Latest Conference Articles

Despite the wealth of choices physicians have in finding drugs to treat hepatitis C infection, two challenges remain in eradicating the disease-price and lack of global screening for the virus.

A lot of attention in the field of multiple sclerosis is being dedicated to neuroprotection and remyelination. Whether these can someday lead to more effective treatments remains to be seen but there is optimism among doctors and researchers alike.

Lise Lotte Gluud, MD, DmSc, shared some of the best practices she and her colleagues learned through their own research at The International Liver Congress 2015 Vienna, Austria.

A lot of work is being put into developing ways to diagnose and treat patients with Alzheimer's Disease now. Even as work for the present is being done researchers are are also looking toward the future and what could be coming down the road.

Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, discussed his hope for hepatologists to better understand the mechanisms that lead from fatty liver to steatohepatitis and subsequently from steatohepatitis to cirrhosis at The International Liver Congress 2015.

The understanding of Alzheimer's Disease has shown a lot of progression in recent years. One area that has not found a definitive new direction is diagnosis, which typically can only be done through autopsy. New technology could allow doctors to see the disease before it affects a person's life.

As with all forms of medicine there are challenges associated with treating patients with hyperkinetic movement disorders. How doctors tackle those challenges can range from work in specialty clinics to consulting with patients through telemedicine.

The opioid epidemic began nearly 30 years ago and since that time small steps have been taken to reverse its effects. The question remains whether too much damage has already been done to fix the problems in a timely manner.

For many years the dangers of opioid addiction have been well known. Taking the steps needed to reverse its impact has been slower in taking hold across the country.

There are some movement disorders that are commonly seen by healthcare professionals and some that fall more into the rare category. Properly diagnosing and treating them can make a big difference in a patient's quality of life.

As one of the first signs of multiple sclerosis acute optic neuritis can be a worrying symptom for patients. Finding the proper treatment can be important in the early stages of diagnosis.

For many patients medication and surgery can be enough to help them maintain their health and control epileptic seizures. Work is also being done in the field to find alternative therapies including medical marijuana and seizure predicting devices.

When medication is not enough to treat epilepsy sometimes surgery can be a good choice for treatment. While the more common methods are also invasive in many ways there are newer procedures being developed that require less recovery time.

Diagnosing patients with epilepsy can often be an involved process as doctors will likely not see the seizures their patients report suffering. Once a diagnosis is made finding the right treatment can also be a challenge as different patient groups will require different types and doses of a variety of medications.

In the treatment of epilepsy there are constantly new drugs being developed to help patients manage their seizures. In the recent past there have been four new medications, each with their own benefits but also with their own risks as well.

For patients with Alzheimer's Disease, as their condition worsens it often falls on other members of their family to make decisions about their course of treatment. What they are expected to do and how they make certain decisions can have long lasting impacts on the care of the people with the disease.

One of the main focus points in the treatment of Alzheimer's Disease is screening patients before they even show symptoms of the condition. This is a part of the process that also includes looking to develop new treatments that could be used in the future.

While Alzheimer's Disease is not a new condition, finding a treatment has been elusive even as more is learned about it. Part of the diagnosis involves knowing what to look for beyond tests of cognition and other aspects of a patient's life.

Researchers are investigating whether microbial therapy can be an effective treatment for several skin and allergic conditions.

The gut microbiota modulates immune development and is an important component of neuroendocrine system. These interactions interfere with neuroendocrine development and, consequently, the patient's immune function.

Dietary amino acids are converted by the luminal microbiome in the gut to a bioactive compound, histamine, which binds to H2R and suppresses MAP kinase signaling and proinflammatory cytokines.

SLIT-tablets have a safety profile suitable for home treatment, as long as the first tablet intake is done under medical supervision. Long-term outcomes seem to differ between grass pollen SLIT-tablet products, and further studies are required.

Comparing safety and efficacy between sublingual immunotherapy and subcutaneous immunotherapy.

Multiple sclerosis, especially in the relapsing form poses a variety of challenges for patient care. Keeping that in mind, the development of medications for the condition also take time to progress.

Developing drugs for conditions like multiple sclerosis takes a long time and a considerable amount of research. How the drugs are used, and changed is a delicate process undertaken between doctors and their patients over the course of the disease.

Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.

Researchers believe they have found a novel therapeutic to target a growth factor pathway that plays a role in liver cancer.

Another investigational diabetes drug appears to have promise for patients with nonalcoholic steatohepatitis, researchers reported at the International Liver Congress in Vienna, Austria.

The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem. But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.

In addition to injection drug use, alcohol consumption puts people at risk of dying from hepatitis C infection by increasing the severity of the disease. A French research study spells out the risks.